Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics cash
Cash and short-term investments held at the end of each period.
Adaptimmune Therapeutics's cash was $26.06M at Jun 30, 2025. For fiscal 2024 it was $151.61M, up 1.1% from the year before. The highest annual figure on record is $372.82M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $151.61M | +1.1% |
| FY2023 | Dec 31, 2023 | $149.96M | -27.3% |
| FY2022 | Dec 31, 2022 | $206.17M | -44.5% |
| FY2021 | Dec 31, 2021 | $371.30M | -0.4% |
| FY2020 | Dec 31, 2020 | $372.82M | +296.5% |
| FY2019 | Dec 31, 2019 | $94.04M | -55.1% |
| FY2018 | Dec 31, 2018 | $209.23M | -1.5% |
| FY2017 | Dec 31, 2017 | $212.51M | -7.2% |
| FY2015 | Jun 30, 2015 | $229.05M | +347.5% |
| FY2014 | Jun 30, 2014 | $51.18M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $26.06M | -88.0% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $59.56M | -59.3% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $151.61M | +1.1% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $186.09M | +13.0% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $217.66M | +4.7% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $146.51M | -12.3% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $149.96M | -27.3% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $164.74M | -18.2% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $207.94M | -20.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $167.13M | -45.4% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $206.17M | -44.5% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $201.38M | -16.7% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $259.80M | -10.4% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $305.93M | -5.2% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $371.30M | -0.4% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $241.84M | -40.2% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $290.00M | -31.5% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $322.55M | +60.7% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $372.82M | +296.5% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $404.35M | +277.3% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $423.31M | +207.2% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $200.76M | +16.3% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $94.04M | -55.1% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $107.18M | -55.7% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $137.81M | +3.4% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $172.63M | +3.9% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $209.23M | -1.5% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $241.90M | +2.5% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $133.22M | -35.4% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $166.19M | -4.8% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $212.51M | -7.2% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $236.09M | +155.0% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $206.18M | +102.8% |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $174.61M | +241.2% |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $229.05M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $92.60M | – |
| Q2 FY2015CQ4 2014 | Dec 31, 2014 | $101.66M | – |
| Q4 FY2014CQ2 2014 | Jun 30, 2014 | $51.18M | – |
See a number that looks wrong?